Lead with cash and GAAP: this season's results show why the adjustments matter

Two numbers, one company

Read Biogen's third-quarter release closely. Revenue rose 11% to $2.8 billion, and its Growth Portfolio rose 49%, helped by a first full quarter of the acquired Apellis products. GAAP diluted EPS was $(0.14). Non-GAAP diluted EPS was $2.62. That is a gap of $2.76 per share, which the company attributes primarily to transaction-related charges.

Sarepta shows the same pattern on a smaller scale. It reported a GAAP operating loss of $9.0 million and non-GAAP operating income of $22.9 million, a swing of roughly $32 million between the two views of one quarter. It also reported positive cash flow.

CompePharma's view is that this gap, not the revenue line, is where the quality of an earnings report is now decided. Executives who treat it as a footnote are making a mistake.

Why the bridge matters this season

Plenty of companies had good headlines. Halozyme grew total revenue 39% and raised guidance for adjusted EBITDA and non-GAAP EPS. Moderna reported 29% revenue growth, raised its 2026 growth outlook to 15%–25% and lifted its expected year-end cash to $8.1–$8.3 billion. PTC reported $182 million from Sephience in the quarter and said it is on track for cash flow breakeven this year.

Growth is easy to read. Whether it is durable and self-funding is harder, and that is what the bridge from adjusted to reported results, and from either to cash, is for. Moderna's GAAP EPS of $0.38 and the roughly $0.2 billion improvement in its GAAP operating expense outlook give investors a figure they can check against the headline. PTC's breakeven language and Sarepta's cash-flow statement do the same job. Biogen's release goes a step further by saying its non-GAAP figure reflects $284 million of acquired IPR&D, upfront and milestone expense, which is the kind of disclosure that shows what sits inside the adjusted number.

Prothena makes the point from the other end. A late-stage biotech reporting $12.0 million of net cash used in operating and investing activities in the quarter and a $272.2 million cash position has little use for adjusted metrics. Cash is the story.

The strongest counter-argument

The obvious objection is that non-GAAP exists for good reason. Deal charges, acquired in-process R&D and integration costs are lumpy and tied to specific transactions. Biogen's GAAP loss comes from an acquisition that, on its own account, is already adding to growth. Judging a company on a quarter distorted by deal accounting would mislead as much as ignoring the charges would.

That is fair, and it is not an argument against adjusted metrics. It is an argument for explaining them. The risk is not that companies adjust. The risk is that the adjusted figure becomes the only one leaders defend, and that the reconciliation sits in a table few people read. Deal-heavy and launch-heavy companies, which describes most of this season's winners, will keep producing large gaps. Without a clear account of the adjustments, those gaps will invite suspicion that the business does not need.

What it means for leaders

The companies that look strongest in this material are the ones that let the reader move easily between measures. Revenue growth, adjusted profit, GAAP results and cash can all be read together, and each reinforces the others. A company with a 49% growth segment and a GAAP loss has a story to tell, but only if it tells all of it.

Management teams should treat the next quarter's release as an exercise in bridge-building. State the largest adjustments in the first paragraph, not the fifteenth. Say which are one-off and which will recur. Give a cash or breakeven marker alongside any adjusted profit figure. Reporting that makes the reader's job easier will outlast any single quarter's beat.

— The Editor